Lamotrigine (All indications)

Cleft lip with or without cleft palate

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10035
R36159		 Blotière (Lamotrigine) (Mixed indications), 2019 Cleft lip with or without cleft palate 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.80 [0.10;2.80] 2/2,997   1,637/1,875,733 1,639 2,997
ref
S8921
R30158		 Holmes (Lamotrigine), 2008 Cleft lip with or without cleft palate isolated 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No 5.93 [1.46;24.07] C 2/684   102/206,224 104 684
ref
Total 2 studies 2.30 [0.32;16.29] 1,743 3,681
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière (Lamotrigine) (Mixed indications), 2019Blotière, 2019 1 0.80[0.10; 2.80]1,6392,99747%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Holmes (Lamotrigine), 2008Holmes, 2008 2 5.93[1.46; 24.07]10468453%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 69% 2.30[0.32; 16.29]1,7433,6810.220.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Mixed indications; 2: Lamotrigine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.30[0.32; 16.29]1,7433,68169%NABlotière (Lamotrigine) (Mixed indications), 2019 Holmes (Lamotrigine), 2008 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.30[0.32; 16.29]1,7433,68169%NABlotière (Lamotrigine) (Mixed indications), 2019 Holmes (Lamotrigine), 2008 2 Tags Adjustment   - No  - No 2.30[0.32; 16.29]1,7433,68169%NABlotière (Lamotrigine) (Mixed indications), 2019 Holmes (Lamotrigine), 2008 2 All studiesAll studies 2.30[0.32; 16.29]1,7433,68169%NABlotière (Lamotrigine) (Mixed indications), 2019 Holmes (Lamotrigine), 2008 20.220.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.30[0.32; 16.29]1,7433,68169%NABlotière (Lamotrigine) (Mixed indications), 2019 Holmes (Lamotrigine), 2008 20.510.01.0

Umbrella review (other published meta-analyses)

Published MATE95% CIn exposedkI2Control groupExposition period Veroniki (NMA)Veroniki (NMA) 1.21[0.45; 3.20]-whatever (meta-analysis)during pregnancy (anytime or not specified)studies7 metaPregmetaPreg 2.30[0.32; 16.29]69%3,681--Blotière (Lamotrigine) (Mixed indications), 2019 Holmes (Lamotrigine), 2008 20.510.01.0